SHP2 Inhibition May Resensitize NSCLC Tumors to ALK Inhibitors [Lung Cancer]

Targeting SHP2 suppresses ALK inhibitor resistance caused by tyrosine kinase reactivation.

from Cancer via ola Kala on Inoreader https://ift.tt/2JDt0cg
via IFTTT